Algeta ASA

AdvanCell Appoints Alpha Therapy Pioneer Andrew Kay as Board Chair to Lead PSMA-Targeted Radiopharmaceutical Development

- AdvanCell has appointed Andrew Kay, former CEO of Algeta ASA, as Chair-elect of its Board of Directors, bringing expertise from the successful $2.9 billion development and commercialization of Xofigo, the first approved alpha therapy. - Kay's appointment comes as AdvanCell advances its lead asset ADVC001, a potentially first-in-class PSMA-targeted alpha therapy, following promising Phase 1 trial results presented at ESMO. - The leadership transition positions AdvanCell to accelerate clinical development of its Lead-212 platform and expand manufacturing capabilities in the US for global late-stage development.